Virtual event to include discussions on our lumateperone, ITI-1284, PDE1 inhibitors and ITI-333 platforms
Webcast scheduled for Wednesday, Oct. 20 from 12:30 to 3:30 p.m. ET
NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a virtual event to discuss the Company’s robust pipeline including lumateperone, ITI-1284, PDE inhibitor platform and ITI-333. The virtual event will take place on Wednesday, October 20, 2021, beginning at 12:30 p.m. ET. and will feature presentations and discussion from the Company’s management team and external key opinion leaders.
The live and archived webcast can be accessed under “Events & Presentations” on the Investor Relations section of the Company’s website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
Burns McClellan, Inc.
Corporate Media Relations W2O Group